Stoke Therapeutics Appoints Ian Smith as Permanent CEO, Boosting Investor Confidence

Stoke Therapeutics has appointed Ian Smith as its permanent CEO, leading to a rise in stock prices. This leadership change is seen as a positive development, bringing fresh perspectives and stability to the company. Investors are optimistic about the potential for growth and innovation in the biotechnology sector under Smith's guidance, enhancing stakeholder confidence in the company's mission to develop therapies for genetic diseases.